Proteomic Portraits Reveal Evolutionarily Conserved and Divergent Responses to Spinal Cord Injury

Michael A Skinnider1, Jason Rogalski1, Seth Tigchelaar2

  • 1Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.

Insights

Researchers identified protein biomarkers in cerebrospinal fluid and serum to predict recovery from acute spinal cord injury (SCI). This discovery aids in evaluating new SCI treatments and guides future preclinical research.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Translational Medicine

Background:

  • Clinical trials for acute spinal cord injury (SCI) treatments often fail due to reliance on lengthy neurological assessments.
  • Current animal models for SCI research may not accurately reflect human injury, hindering therapeutic development.
  • There is a critical need for objective, efficient outcome measures in SCI clinical trials.

Purpose of the Study:

  • To develop novel protein biomarkers for assessing SCI severity and predicting neurological recovery.
  • To establish reliable biochemical outcome measures for both human and animal SCI studies.
  • To bridge the gap between preclinical research and clinical application for SCI therapies.

Main Methods:

  • Targeted proteomic analysis of cerebrospinal fluid and serum from 111 acute SCI patients.
  • Parallel proteomic analysis in a porcine model of SCI.
  • Development and validation of a prognostic model for neurological improvement using identified biomarkers.

Main Results:

  • Identified protein biomarkers indicative of SCI severity and recovery.
  • Developed a prognostic model for 6-month neurological improvement with high accuracy (AUC 0.91).
  • Established glial fibrillary acidic protein (GFAP) in cerebrospinal fluid as a cross-species biochemical outcome measure.

Conclusions:

  • Protein biomarkers can significantly improve the efficiency and objectivity of SCI clinical trials.
  • GFAP serves as a validated biochemical marker for SCI outcomes in both humans and pigs.
  • This research facilitates the evaluation of novel SCI therapies and directs future preclinical investigations.